One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis
Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment. Methods: All patients receiv...
Uloženo v:
| Vydáno v: | European journal of neurology Ročník 16; číslo 11; s. 1202 - 1209 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford, UK
Blackwell Publishing Ltd
01.11.2009
|
| Témata: | |
| ISSN: | 1351-5101, 1468-1331, 1468-1331 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment.
Methods: All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single‐centre, prospective and post‐marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed‐up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of ≥1 point in the Expanded Disability Status Scale (EDSS) during the follow‐up period.
Results: Out of 454 RR‐MS patients starting IFNB therapy, data coming from 394 patients with a mean follow‐up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow‐up. Less than 1/3 (30.4%) of the patients satisfied the criterion of ‘poor responders’. Patients presenting new lesions on T2‐weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow‐up period (HR 16.8, 95% CI 7.6–37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10‐fold increase for each new lesion.
Conclusions: Developing new T2‐hyperintense lesions during IFNB treatment was the best predictor of long‐term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. |
|---|---|
| AbstractList | To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting multiple sclerosis (RR-MS) patients with sustained disability progression during interferon beta (IFNB) treatment.BACKGROUND AND PURPOSETo define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting multiple sclerosis (RR-MS) patients with sustained disability progression during interferon beta (IFNB) treatment.All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single-centre, prospective and post-marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed-up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of > or =1 point in the Expanded Disability Status Scale (EDSS) during the follow-up period.METHODSAll patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single-centre, prospective and post-marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed-up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of > or =1 point in the Expanded Disability Status Scale (EDSS) during the follow-up period.Out of 454 RR-MS patients starting IFNB therapy, data coming from 394 patients with a mean follow-up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow-up. Less than 1/3 (30.4%) of the patients satisfied the criterion of 'poor responders'. Patients presenting new lesions on T2-weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow-up period (HR 16.8, 95% CI 7.6-37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10-fold increase for each new lesion.RESULTSOut of 454 RR-MS patients starting IFNB therapy, data coming from 394 patients with a mean follow-up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow-up. Less than 1/3 (30.4%) of the patients satisfied the criterion of 'poor responders'. Patients presenting new lesions on T2-weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow-up period (HR 16.8, 95% CI 7.6-37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10-fold increase for each new lesion.Developing new T2-hyperintense lesions during IFNB treatment was the best predictor of long-term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders.CONCLUSIONSDeveloping new T2-hyperintense lesions during IFNB treatment was the best predictor of long-term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting multiple sclerosis (RR-MS) patients with sustained disability progression during interferon beta (IFNB) treatment. All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single-centre, prospective and post-marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed-up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of > or =1 point in the Expanded Disability Status Scale (EDSS) during the follow-up period. Out of 454 RR-MS patients starting IFNB therapy, data coming from 394 patients with a mean follow-up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow-up. Less than 1/3 (30.4%) of the patients satisfied the criterion of 'poor responders'. Patients presenting new lesions on T2-weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow-up period (HR 16.8, 95% CI 7.6-37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10-fold increase for each new lesion. Developing new T2-hyperintense lesions during IFNB treatment was the best predictor of long-term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment. Methods: All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single‐centre, prospective and post‐marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed‐up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of ≥1 point in the Expanded Disability Status Scale (EDSS) during the follow‐up period. Results: Out of 454 RR‐MS patients starting IFNB therapy, data coming from 394 patients with a mean follow‐up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow‐up. Less than 1/3 (30.4%) of the patients satisfied the criterion of ‘poor responders’. Patients presenting new lesions on T2‐weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow‐up period (HR 16.8, 95% CI 7.6–37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10‐fold increase for each new lesion. Conclusions: Developing new T2‐hyperintense lesions during IFNB treatment was the best predictor of long‐term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting multiple sclerosis (RR‐MS) patients with sustained disability progression during interferon beta (IFNB) treatment. Methods: All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single‐centre, prospective and post‐marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed‐up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of ≥1 point in the Expanded Disability Status Scale (EDSS) during the follow‐up period. Results: Out of 454 RR‐MS patients starting IFNB therapy, data coming from 394 patients with a mean follow‐up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow‐up. Less than 1/3 (30.4%) of the patients satisfied the criterion of ‘poor responders’. Patients presenting new lesions on T2‐weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow‐up period (HR 16.8, 95% CI 7.6–37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10‐fold increase for each new lesion. Conclusions: Developing new T2‐hyperintense lesions during IFNB treatment was the best predictor of long‐term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting multiple sclerosis (RR-MS) patients with sustained disability progression during interferon beta (IFNB) treatment.Methods: All patients receiving treatment with one of the available IFNB formulations for at least 1 year were included in this single-centre, prospective and post-marketing study. Demographic, clinical and MRI data were collected at IFNB start and at 1 year of therapy; patients were followed-up at least yearly. Poor clinical response was defined as the occurrence of a sustained disability progression of greater than or equal to 1 point in the Expanded Disability Status Scale (EDSS) during the follow-up period.Results: Out of 454 RR-MS patients starting IFNB therapy, data coming from 394 patients with a mean follow-up of 4.8 (2.4) years were analysed. Sixty patients were excluded because of too short follow-up. Less than 1-3 (30.4%) of the patients satisfied the criterion of 'poor responders'. Patients presenting new lesions on T2-weighted MRI scan after 1 year of therapy (compared with baseline) had a higher risk of being poor responder to treatment with IFNB during the follow-up period (HR 16.8, 95% CI 7.6-37.1, P < 0.001). An augmented risk increasing the number of lesions was observed, with a 10-fold increase for each new lesion.Conclusions: Developing new T2-hyperintense lesions during IFNB treatment was the best predictor of long-term poor response to therapy. MRI scans performed after 1 year of IFNB treatment may be useful in contributing to early identification of poor responders. |
| Author | Gallo, V. Prosperini, L. Pozzilli, C. Petsas, N. Borriello, G. |
| Author_xml | – sequence: 1 givenname: L. surname: Prosperini fullname: Prosperini, L. organization: Multiple Sclerosis Centre, Department of Neurological Sciences, S. Andrea Hospital, "La Sapienza" University, Rome, Italy – sequence: 2 givenname: V. surname: Gallo fullname: Gallo, V. organization: Multiple Sclerosis Centre, Department of Neurological Sciences, S. Andrea Hospital, "La Sapienza" University, Rome, Italy – sequence: 3 givenname: N. surname: Petsas fullname: Petsas, N. organization: Neurological Centre of Latium, Rome, Italy – sequence: 4 givenname: G. surname: Borriello fullname: Borriello, G. organization: Multiple Sclerosis Centre, Department of Neurological Sciences, S. Andrea Hospital, "La Sapienza" University, Rome, Italy – sequence: 5 givenname: C. surname: Pozzilli fullname: Pozzilli, C. organization: Multiple Sclerosis Centre, Department of Neurological Sciences, S. Andrea Hospital, "La Sapienza" University, Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19538207$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtvEzEURi3Uij7gLyCvYDVTP-ZhL0CiVSiV0lRCVO3Ocjx3JAfHM9iOSP49HtJm0QXgjW3dc64f3xk68oMHhDAlJc3jYlXSqhEF5ZyWjBBZEtYSUW5fodND4SiveU2LmhJ6gs5iXBGSMUZeoxMqay4YaU_R_Z2HYgc64NtvNzga7fEYoLMmRWyc9dZohwPEcfARcBqw9QlCD2HweAlJ5z1eb1yyo4Osu1yINr5Bx712Ed4-zefo_svs-9XXYn53fXP1eV6YireiaMAw1nfQ9ULKCmi77LURom6ZaZpGNMA477SuWUWk6VotWdUT2fNOTNevCT9HH_Z9xzD83EBMam2jAee0h2ETVcuzWUsuM_n-rySjVDDGaAbfPYGb5Ro6NQa71mGnnr8sA5_2gMlPjQF6ZWzSyQ4-BW2dokRNGamVmqJQUxRqykj9yUhtcwPxosHhjH-rH_fqL-tg99-emi1m0yr7xd63McH24OvwQzUtb2v1sLhWcvF4OSe3c8X4b0fstuE |
| CitedBy_id | crossref_primary_10_1177_1756285613491520 crossref_primary_10_1212_NXI_0000000000000379 crossref_primary_10_1177_1352458517726657 crossref_primary_10_1016_j_msard_2019_101406 crossref_primary_10_1177_17562864241229325 crossref_primary_10_1007_s00062_015_0430_y crossref_primary_10_1038_nrneurol_2013_146 crossref_primary_10_1186_s12883_014_0240_x crossref_primary_10_1007_s40263_020_00749_x crossref_primary_10_1186_s12883_018_1066_8 crossref_primary_10_7224_1537_2073_14_3_105 crossref_primary_10_1038_nrneurol_2011_22 crossref_primary_10_36290_neu_2018_104 crossref_primary_10_1016_j_yexcr_2011_03_002 crossref_primary_10_1080_01616412_2021_1967680 crossref_primary_10_1016_j_msard_2016_05_012 crossref_primary_10_1017_cjn_2015_302 crossref_primary_10_1017_S0317167100014244 crossref_primary_10_3390_ijms26167756 crossref_primary_10_1177_1352458520936823 crossref_primary_10_1146_annurev_med_042910_135833 crossref_primary_10_1371_journal_pone_0169546 crossref_primary_10_1016_S1474_4422_14_70068_7 crossref_primary_10_1177_1352458517698052 crossref_primary_10_1007_s00739_016_0332_z crossref_primary_10_1007_s11940_017_0454_5 crossref_primary_10_1177_1352458516650739 crossref_primary_10_1212_WNL_0b013e318259e13a crossref_primary_10_1177_1756286418791103 crossref_primary_10_1186_s12883_016_0699_8 crossref_primary_10_1038_s41598_020_69383_3 crossref_primary_10_1007_s00415_012_6775_0 crossref_primary_10_1111_ene_12119 crossref_primary_10_1586_ern_11_196 crossref_primary_10_1177_1352458513502399 crossref_primary_10_1007_s00415_021_10823_z crossref_primary_10_1016_j_jns_2015_12_043 crossref_primary_10_1016_j_jns_2020_116827 crossref_primary_10_1177_1352458514527863 crossref_primary_10_1016_j_cyto_2015_01_004 crossref_primary_10_1016_j_msard_2014_08_003 crossref_primary_10_1016_j_jns_2017_10_015 crossref_primary_10_1038_tpj_2015_85 crossref_primary_10_1016_j_jns_2014_02_017 crossref_primary_10_1097_WCO_0000000000000333 crossref_primary_10_1002_ana_24747 crossref_primary_10_1186_s12883_016_0648_6 crossref_primary_10_1212_WNL_0000000000002830 crossref_primary_10_1371_journal_pone_0019262 crossref_primary_10_1016_j_jns_2012_08_027 crossref_primary_10_1111_ene_13536 crossref_primary_10_1517_17425247_2014_943181 crossref_primary_10_1016_j_msard_2015_07_007 crossref_primary_10_1007_s00115_015_4439_x crossref_primary_10_1007_s13167_011_0086_x crossref_primary_10_1016_j_jns_2018_01_004 crossref_primary_10_1155_2023_8843488 crossref_primary_10_3174_ajnr_A4539 crossref_primary_10_1007_s13167_010_0020_7 crossref_primary_10_1038_nrneurol_2015_85 crossref_primary_10_1177_2055217315589775 crossref_primary_10_1586_ern_13_52 crossref_primary_10_1016_j_ncl_2017_08_010 crossref_primary_10_1016_j_neurol_2013_08_003 crossref_primary_10_1136_jnnp_2015_310597 crossref_primary_10_1016_S0140_6736_12_61768_1 crossref_primary_10_1586_14737175_2015_1023711 crossref_primary_10_1016_j_clim_2015_06_015 crossref_primary_10_1177_1352458513513058 crossref_primary_10_1212_CPJ_0000000000000254 crossref_primary_10_1097_WCO_0000000000000204 crossref_primary_10_1177_1352458514555786 crossref_primary_10_1212_CON_0000000000000329 crossref_primary_10_1097_WCO_0000000000000319 crossref_primary_10_1016_j_msard_2015_09_002 crossref_primary_10_1177_2040622313479137 crossref_primary_10_7224_1537_2073_2016_051 crossref_primary_10_1016_j_nrleng_2021_06_006 crossref_primary_10_1111_ene_12695 crossref_primary_10_1177_1756285617708911 crossref_primary_10_1177_1352458512460605 crossref_primary_10_1111_j_1468_1331_2010_03248_x crossref_primary_10_1016_S1474_4422_11_70023_0 crossref_primary_10_1007_s40263_013_0042_5 crossref_primary_10_1186_1471_2377_11_26 crossref_primary_10_1002_ana_23758 crossref_primary_10_1212_WNL_0000000000000036 crossref_primary_10_1212_WNL_0000000000006810 crossref_primary_10_1111_ane_12269 crossref_primary_10_1212_CON_0000000000000738 crossref_primary_10_1155_2014_436764 crossref_primary_10_1177_1352458517751049 |
| Cites_doi | 10.1007/s00415-007-0584-x 10.1002/ana.20224 10.1002/ana.20740 10.1212/01.WNL.0000036271.49066.06 10.1002/ana.410430114 10.1093/brain/awf177 10.1212/WNL.43.4.662 10.1016/S0140-6736(98)03334-0 10.1212/01.WNL.0000078888.07196.0B 10.1177/1352458506071309 10.1212/01.WNL.0000078885.05053.7D 10.1212/WNL.43.4.655 10.1007/s00415-005-0885-x 10.1007/s00415-005-0748-5 10.1191/1352458505ms1173oa 10.1177/135245850200800109 10.1136/jnnp.2007.130229 10.1017/S0317167100053804 10.1177/135245859800400501 10.1093/brain/121.1.3 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P 10.1002/ana.21102 10.1212/WNL.33.11.1444 10.1002/ana.410390304 10.1136/jnnp.74.7.946 10.1007/s00415-005-0979-5 10.1177/1352458507085555 10.1002/ana.410390104 10.1002/ana.1032 |
| ContentType | Journal Article |
| Copyright | 2009 The Author(s). Journal compilation © 2009 EFNS |
| Copyright_xml | – notice: 2009 The Author(s). Journal compilation © 2009 EFNS |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 7X8 |
| DOI | 10.1111/j.1468-1331.2009.02708.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Neurosciences Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-1331 |
| EndPage | 1209 |
| ExternalDocumentID | 19538207 10_1111_j_1468_1331_2009_02708_x ENE2708 ark_67375_WNG_9NXBL0ML_2 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 169 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAMMB AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCMX ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AFBPY AFEBI AFGKR AFKRA AFRAH AFWVQ AFZJQ AGQPQ AGXDD AHMBA AIACR AIDQK AIDYY AIQQE AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F5P FEDTE FUBAC FYBCS FYUFA G-S G.N GODZA GROUPED_DOAJ H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PHGZM PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ TEORI UB1 UKHRP W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAHHS ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE ESX RIG AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7T5 7TK H94 7X8 |
| ID | FETCH-LOGICAL-c4378-6ec22fdedf8994e17bfac88572c66686e233daa52409cd7a924f09f3d85382503 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 102 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000270900700009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1351-5101 1468-1331 |
| IngestDate | Tue Aug 05 11:01:37 EDT 2025 Tue Aug 05 11:35:04 EDT 2025 Thu Apr 03 07:04:07 EDT 2025 Tue Nov 18 22:28:09 EST 2025 Sat Nov 29 04:04:21 EST 2025 Wed Jan 22 16:27:18 EST 2025 Sun Sep 21 06:18:54 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4378-6ec22fdedf8994e17bfac88572c66686e233daa52409cd7a924f09f3d85382503 |
| Notes | ArticleID:ENE2708 istex:FC4EEB0C94B0B1068982C8C801AFC93BDD5DD32A ark:/67375/WNG-9NXBL0ML-2 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 19538207 |
| PQID | 21182221 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_734095939 proquest_miscellaneous_21182221 pubmed_primary_19538207 crossref_citationtrail_10_1111_j_1468_1331_2009_02708_x crossref_primary_10_1111_j_1468_1331_2009_02708_x wiley_primary_10_1111_j_1468_1331_2009_02708_x_ENE2708 istex_primary_ark_67375_WNG_9NXBL0ML_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-11 November 2009 2009-11-00 2009-Nov 20091101 |
| PublicationDateYYYYMMDD | 2009-11-01 |
| PublicationDate_xml | – month: 11 year: 2009 text: 2009-11 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | European journal of neurology |
| PublicationTitleAlternate | Eur J Neurol |
| PublicationYear | 2009 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN Beta Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293. Li DK, Paty DW. Magnetic Resonance Imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis. Ann Neurol 1999; 42: 197-206. Rio J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-1695. The IFN beta Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN Beta Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294. O'Rourke K, Walsh C, Hutchinson M. Outcome of Beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol 2007; 254: 1547-1554. Koudriavtseva T, Pozzilli C, Fiorelli M, et al. Determinants of Gd-enhanced MRI response to IFN beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 1998; 4: 403-407. Rio J, Tintoré M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005; 252: 795-800. O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342. Rio J, Nos C, Tintoré M, et al. Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352. Fisher E, Rudick RA, Simon JH, et al. Eight year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504. Durelli L, Berbero P, Bergui M, et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J Neurol Neurosurg Psychiatry 2008; 79: 646-651. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51. Miller DH, Grossman R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24. Roullet E, Dominique P, Le Canuet P, et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Neurology 2003; 60(Suppl. 1): A168. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555. Kurtzke JF. Rating neurological impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 2003; 33: 1444-1452. Dubois BD, Keenan E, Porter BE, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003; 74: 946-949. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group. Ann Neurol 1998; 43: 79-87. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines form the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189. Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. J Neurol 2005; 252: 1455-1458. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554. Freedman MS, Patry DG, Grand'Maison F, et al. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-168. 2001; 50 2002; 59 1996; 39 2005; 252 1993; 43 2006; 59 2002; 8 2008; 14 2006; 253 2008; 79 1999; 42 1998; 352 1998; 43 2003; 74 2007; 13 2003; 33 2004; 31 2007; 254 2002; 125 2004; 56 2007; 61 2003; 60 2003; 61 1998; 121 1998; 4 2005; 11 e_1_2_9_30_2 e_1_2_9_10_2 Roullet E (e_1_2_9_12_2) 2003; 60 e_1_2_9_31_2 e_1_2_9_11_2 e_1_2_9_14_2 e_1_2_9_13_2 e_1_2_9_16_2 e_1_2_9_15_2 e_1_2_9_18_2 e_1_2_9_17_2 e_1_2_9_19_2 e_1_2_9_21_2 e_1_2_9_20_2 e_1_2_9_23_2 e_1_2_9_22_2 e_1_2_9_7_2 e_1_2_9_6_2 e_1_2_9_5_2 e_1_2_9_4_2 e_1_2_9_3_2 e_1_2_9_2_2 e_1_2_9_9_2 e_1_2_9_8_2 e_1_2_9_25_2 e_1_2_9_24_2 e_1_2_9_27_2 e_1_2_9_26_2 e_1_2_9_29_2 e_1_2_9_28_2 |
| References_xml | – reference: Roullet E, Dominique P, Le Canuet P, et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Neurology 2003; 60(Suppl. 1): A168. – reference: Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309. – reference: Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN Beta Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667. – reference: Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294. – reference: Kurtzke JF. Rating neurological impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 2003; 33: 1444-1452. – reference: Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group. Ann Neurol 1998; 43: 79-87. – reference: The IFN beta Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN Beta Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661. – reference: Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293. – reference: Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16. – reference: Miller DH, Grossman R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24. – reference: O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342. – reference: Dubois BD, Keenan E, Porter BE, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003; 74: 946-949. – reference: Rio J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484. – reference: McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines form the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127. – reference: O'Rourke K, Walsh C, Hutchinson M. Outcome of Beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol 2007; 254: 1547-1554. – reference: Rio J, Tintoré M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005; 252: 795-800. – reference: Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555. – reference: Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554. – reference: Koudriavtseva T, Pozzilli C, Fiorelli M, et al. Determinants of Gd-enhanced MRI response to IFN beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 1998; 4: 403-407. – reference: Freedman MS, Patry DG, Grand'Maison F, et al. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-168. – reference: Fisher E, Rudick RA, Simon JH, et al. Eight year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420. – reference: McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51. – reference: Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306. – reference: Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-1695. – reference: Li DK, Paty DW. Magnetic Resonance Imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis. Ann Neurol 1999; 42: 197-206. – reference: Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189. – reference: Rio J, Nos C, Tintoré M, et al. Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352. – reference: Durelli L, Berbero P, Bergui M, et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J Neurol Neurosurg Psychiatry 2008; 79: 646-651. – reference: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504. – reference: Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. J Neurol 2005; 252: 1455-1458. – volume: 42 start-page: 197 year: 1999 end-page: 206 article-title: Magnetic Resonance Imaging results of the PRISMS trial: a randomized, double‐blind, placebo‐controlled study of interferon beta‐1a in relapsing‐remitting multiple sclerosis. Prevention of relapses and disability by interferon beta‐1a subcutaneously in multiple sclerosis publication-title: Ann Neurol – volume: 254 start-page: 1547 year: 2007 end-page: 1554 article-title: Outcome of Beta‐interferon treatment in relapsing‐remitting multiple sclerosis: a Bayesian analysis publication-title: J Neurol – volume: 39 start-page: 285 year: 1996 end-page: 294 article-title: Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) publication-title: Ann Neurol – volume: 121 start-page: 3 year: 1998 end-page: 24 article-title: The role of magnetic resonance techniques in understanding and managing multiple sclerosis publication-title: Brain – volume: 59 start-page: 1412 year: 2002 end-page: 1420 article-title: Eight year follow‐up study of brain atrophy in patients with MS publication-title: Neurology – volume: 11 start-page: 306 year: 2005 end-page: 309 article-title: Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis publication-title: Mult Scler – volume: 14 start-page: 479 year: 2008 end-page: 484 article-title: Relationship between MRI lesion activity and response to IFN‐beta in relapsing‐remitting multiple sclerosis patients publication-title: Mult Scler – volume: 61 start-page: 184 year: 2003 end-page: 189 article-title: Clinical characteristics of responders to interferon therapy for relapsing MS publication-title: Neurology – volume: 56 start-page: 548 year: 2004 end-page: 555 article-title: Defining interferon beta response status in multiple sclerosis patients publication-title: Ann Neurol – volume: 61 start-page: 300 year: 2007 end-page: 306 article-title: New natural history of interferon beta‐treated relapsing multiple sclerosis publication-title: Ann Neurol – volume: 352 start-page: 1498 year: 1998 end-page: 1504 article-title: Randomised double‐blind placebo‐controlled study of interferon beta‐1a in relapsing/remitting multiple sclerosis publication-title: Lancet – volume: 61 start-page: 551 year: 2003 end-page: 554 article-title: Interrupted therapy: stopping and switching of the beta‐interferons prescribed for MS publication-title: Neurology – volume: 4 start-page: 403 year: 1998 end-page: 407 article-title: Determinants of Gd‐enhanced MRI response to IFN beta‐1a treatment in relapsing‐remitting multiple sclerosis publication-title: Mult Scler – volume: 253 start-page: 287 year: 2006 end-page: 293 article-title: Predictors of long‐term clinical response to interferon beta therapy in relapsing multiple sclerosis publication-title: J Neurol – volume: 13 start-page: 336 year: 2007 end-page: 342 article-title: Predicting beta‐interferon failure in relapsing‐remitting multiple sclerosis publication-title: Mult Scler – volume: 59 start-page: 344 year: 2006 end-page: 352 article-title: Defining the response to interferon beta in relapsing‐remitting multiple sclerosis patients publication-title: Ann Neurol – volume: 8 start-page: 40 year: 2002 end-page: 51 article-title: The role of MRI as surrogate outcome measure in multiple sclerosis publication-title: Mult Scler – volume: 43 start-page: 655 year: 1993 end-page: 661 article-title: Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double‐blind, placebo‐controlled trial. The IFN Beta Multiple Sclerosis Study Group publication-title: Neurology – volume: 43 start-page: 79 year: 1998 end-page: 87 article-title: Magnetic resonance studies of intramuscular interferon beta‐1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group publication-title: Ann Neurol – volume: 252 start-page: 1455 year: 2005 end-page: 1458 article-title: The distribution of magnetic resonance imaging response to interferon beta‐1b in multiple sclerosis publication-title: J Neurol – volume: 79 start-page: 646 year: 2008 end-page: 651 article-title: MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS publication-title: J Neurol Neurosurg Psychiatry – volume: 125 start-page: 1676 year: 2002 end-page: 1695 article-title: Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance publication-title: Brain – volume: 252 start-page: 795 year: 2005 end-page: 800 article-title: Interferon beta in relapsing‐remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre publication-title: J Neurol – volume: 31 start-page: 157 year: 2004 end-page: 168 article-title: Treatment optimization in multiple sclerosis publication-title: Can J Neurol Sci – volume: 60 start-page: A168 issue: Suppl. 1 year: 2003 article-title: Application of different criteria for clinical response to beta‐interferon in relapsing‐remitting multiple sclerosis publication-title: Neurology – volume: 50 start-page: 121 year: 2001 end-page: 127 article-title: Recommended diagnostic criteria for multiple sclerosis: guidelines form the International Panel on the diagnosis of Multiple Sclerosis publication-title: Ann Neurol – volume: 39 start-page: 6 year: 1996 end-page: 16 article-title: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force publication-title: Ann Neurol – volume: 74 start-page: 946 year: 2003 end-page: 949 article-title: Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre publication-title: J Neurol Neurosurg Psychiatry – volume: 43 start-page: 662 year: 1993 end-page: 667 article-title: Interferon beta‐1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double‐blind, placebo‐controlled trial. UBC MS/MRI Study Group and the IFN Beta Multiple Sclerosis Study Group publication-title: Neurology – volume: 33 start-page: 1444 year: 2003 end-page: 1452 article-title: Rating neurological impairment in multiple sclerosis. An expanded disability status scale (EDSS) publication-title: Neurology – ident: e_1_2_9_10_2 doi: 10.1007/s00415-007-0584-x – ident: e_1_2_9_24_2 doi: 10.1002/ana.20224 – ident: e_1_2_9_13_2 doi: 10.1002/ana.20740 – ident: e_1_2_9_29_2 doi: 10.1212/01.WNL.0000036271.49066.06 – ident: e_1_2_9_6_2 doi: 10.1002/ana.410430114 – ident: e_1_2_9_28_2 doi: 10.1093/brain/awf177 – ident: e_1_2_9_5_2 doi: 10.1212/WNL.43.4.662 – ident: e_1_2_9_4_2 doi: 10.1016/S0140-6736(98)03334-0 – ident: e_1_2_9_15_2 doi: 10.1212/01.WNL.0000078888.07196.0B – ident: e_1_2_9_17_2 doi: 10.1177/1352458506071309 – ident: e_1_2_9_30_2 doi: 10.1212/01.WNL.0000078885.05053.7D – ident: e_1_2_9_2_2 doi: 10.1212/WNL.43.4.655 – ident: e_1_2_9_21_2 doi: 10.1007/s00415-005-0885-x – ident: e_1_2_9_9_2 doi: 10.1007/s00415-005-0748-5 – ident: e_1_2_9_31_2 doi: 10.1191/1352458505ms1173oa – ident: e_1_2_9_23_2 doi: 10.1177/135245850200800109 – ident: e_1_2_9_27_2 doi: 10.1136/jnnp.2007.130229 – ident: e_1_2_9_22_2 doi: 10.1017/S0317167100053804 – ident: e_1_2_9_26_2 doi: 10.1177/135245859800400501 – ident: e_1_2_9_18_2 doi: 10.1093/brain/121.1.3 – ident: e_1_2_9_7_2 doi: 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P – ident: e_1_2_9_11_2 doi: 10.1002/ana.21102 – ident: e_1_2_9_14_2 doi: 10.1212/WNL.33.11.1444 – ident: e_1_2_9_3_2 doi: 10.1002/ana.410390304 – ident: e_1_2_9_8_2 doi: 10.1136/jnnp.74.7.946 – ident: e_1_2_9_16_2 doi: 10.1007/s00415-005-0979-5 – ident: e_1_2_9_25_2 doi: 10.1177/1352458507085555 – volume: 60 start-page: A168 issue: 1 year: 2003 ident: e_1_2_9_12_2 article-title: Application of different criteria for clinical response to beta‐interferon in relapsing‐remitting multiple sclerosis publication-title: Neurology – ident: e_1_2_9_20_2 doi: 10.1002/ana.410390104 – ident: e_1_2_9_19_2 doi: 10.1002/ana.1032 |
| SSID | ssj0002720 |
| Score | 2.3119867 |
| Snippet | Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting... Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing‐remitting... To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting multiple sclerosis (RR-MS)... Background and purpose: To define the predictive value of clinical and magnetic resonance imaging (MRI) characteristics in identifying relapsing-remitting... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1202 |
| SubjectTerms | Adolescent Adult Age of Onset Child Disease Progression Female Follow-Up Studies Humans interferon beta Interferon-beta - therapeutic use Longitudinal Studies magnetic resonance imaging Magnetic Resonance Imaging - methods Male Middle Aged multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Predictive Value of Tests response to therapy Risk Factors Severity of Illness Index Time Factors Treatment Outcome |
| Title | One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis |
| URI | https://api.istex.fr/ark:/67375/WNG-9NXBL0ML-2/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1468-1331.2009.02708.x https://www.ncbi.nlm.nih.gov/pubmed/19538207 https://www.proquest.com/docview/21182221 https://www.proquest.com/docview/734095939 |
| Volume | 16 |
| WOSCitedRecordID | wos000270900700009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5Bi7hR3gTB4gPiFpQ4ThwfKexCpd2AKqrdm-V1HKmiylZJWrU3fgK_sb-kM0520aIiVYhbImcix57XF88D4G2JJjFyEaWf8TQUqYlCRWBliaoQra3hRvlE4aksinyxUN-G-CfKhenrQ2x-uJFkeH1NAm6W7Z9CjggoSeKh7CSXUf6e_MlYxNTMYH5QbJQyHTd67JXGIbHhdlDPjS_aslS7tOgXN7mh216tN0uTvf_5QQ_hweCcsg89Nz2CO65-DPdnw_H7E5h_rd3Vz1-XKB1sdnjAWtwXdtrQeNeydZIla_q4W8e6FaNyFE3lmlXNlq4zeM_WMYxIfoID7XH7FI4m4-8fv4RDZ4bQigR3MnOW86p0ZYVwTbhYLitj8zyV3CIcyjPHk6Q0JkV3QdlSGgR5VaSqpETnACFplDyDnXpVuxfAUlEagbhU5FkplIgNEWdWGDTeFvVRAHK9C9oOZcupe8aJ3oIvuaZ1o6aaSvt10xcBxBvK0750xy1o3vmN3hCY5geFvslUz4vPWhWL_Wk0m2oewJs1J2gUSDplMbVbnbWaE2TjPA6A_eUJmQhfD1oF8Lznod_zU7RAkQwg86xy64nrcTGmq5f_SvgKdrrmzL2Ge_a8O26bEdyVi3wEu58OJ0fTkZema3HGGUY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB6hFkEv_NOGv_qAuAUljhPHR1pt6YrdgFDR7s3yOo5UUWWrJK3KjUfgGXkSZpzsokVFqhC3RM5E9njGM5_tmQF4XaJJjFxE4Wc8DUVqolARWFngUojW1nCjfKDwRBZFPp-rT0M5IIqF6fNDrDfcSDP8ek0KThvSf2o5QqAkiYe8k1xG-Vt0KLcF-h1Ux2E2LtbLMh04evSVxiEJ4ua1nmv_tGGrtontV9c5opt-rTdMR_f_65AewL3BP2XveoF6CLdc_QjuTIcT-Mcw-1i7n99_fEMFYdPPY9bi1LDzhtq7lq3iLFnTX711rFsyykjRVK5Z1mzhOoPvbHWNEcnPsKE9bZ_Al6PRyeFxOBRnCK1IcDIzZzmvSldWiNiEi-WiMjbPU8ktIqI8czxJSmNS9BiULaVBnFdFqkpK9A8QlUbJU9iql7XbA5aK0giEpiLPSqFEbIg4s8Kg_ba4JAUgV9Og7ZC5nAponOkNBJNr4hvV1VTa801fBRCvKc_77B03oHnjZ3pNYJqvdPtNpnpWvNeqmB9MoulE8wD2V6KgUSfpoMXUbnnRak6ojfM4APaXL2QifEpoFcBuL0S_-6eIQZEMIPOycuOO61Exoqdn_0q4D3ePT3Bkk3Hx4Tns-HMzH3X5Ara65sK9hNv2sjttm1des34B3P8c6Q |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hXVRx4U0JFOoD4haUOM7DR2h3oSIbqoqqe7O8sSNVVNlVkqJy4yfwG_klzDjZRYuKVCFuiZyJHM_ziz0zAK8MusTABpR-xmNfxDrwJYGVBZpC9Laaa-kShfO0KLL5XB4P7YAoF6avD7H54Uaa4ew1KbhdmepPLUcIFEXhUHeSp0H2BgPKsaCeMiMYH55MT_ONYaYtR4e_4tAnUdw-2HPtu7a81ZgW_uq6UHQ7snWuaXrvv37Ufbg7RKjsbS9SD-CWrR_CzmzYg38EZ59q-_P7j2-oImx2csRaZA5bNTTetWydacma_vCtZd2SUU2KprLNsmYL22m8Z-uDjEh-gQPtefsYTqeTzwcf_KE9g1-KCNmZ2JLzylhTIWYTNkwXlS6zLE55iZgoSyyPIqN1jDGDLE2qEelVgawigxEC4tIgegKjelnbp8BiYbRAcCqyxAgpQk3ESSk0evASjZIH6ZoNqhxql1MLjQu1hWEyRetGnTWlcuumrjwIN5Srvn7HDWheO05vCHTzhc6_pbE6K94rWczf5cEsV9yD_bUoKNRK2mrRtV1etooTbuM89ID95Yk0Eq4otPRgtxei3_OTtEBB6kHiZOXGE1eTYkJXz_6VcB92jg-nKj8qPj6HO27jzKVd7sGoay7tC7hdfu3O2-bloFq_AMyWHZI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=One-year+MRI+scan+predicts+clinical+response+to+interferon+beta+in+multiple+sclerosis&rft.jtitle=European+journal+of+neurology&rft.au=Prosperini%2C+L&rft.au=Gallo%2C+V&rft.au=Petsas%2C+N&rft.au=Borriello%2C+G&rft.date=2009-11-01&rft.issn=1351-5101&rft.volume=16&rft.issue=11&rft.spage=1202&rft.epage=1209&rft_id=info:doi/10.1111%2Fj.1468-1331.2009.02708.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon |